Merck siphons off Gardasil CDC supplies again as global sales surge

Gardasil 9
Global sales of Gardasil and Gardasil 9 were up 27% in Q3, although only 3% in the U.S. The HPV vaccines have turned int more than $3 billion in sales through September. (Merck)

Merck & Co. won’t be able to fully meet global demand for HPV vaccine Gardasil until after 2023 when it completes production of a couple of manufacturing plants. So for now, the drugmaker is again turning to the CDC to borrow doses. 

The company this month borrowed Gardasil 9 doses from the U.S. Centers for Disease and Control and Prevention’s (CDC) Pediatric Vaccine Stockpile to help cover vaccinations in the U.S., which will allow Merck to produce more for other parts of the world where demand is outrunning supply. The move will cost Merck about $120 million in Q4 sales, it said. 

“These doses will be allocated to support routine vaccination in the United States and will allow the company to manufacture doses for other parts of the world, including regions where some of the most vulnerable populations live,” the Kenilworth, New Jersey-based company said in its Q3 earnings. 

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

RELATED: Merck to build Gardasil 9 plant and add 425 jobs, but will cut 150 elsewhere

Sales of Gardasil hit $1.32 billion in Q3, making Merck’s Human Papillomavirus (HPV) vaccines its second best selling products behind cancer phenom Keytruda. The Gardasil portfolio has turned in just over $3 billion in sales through September. While Gardasil sales globally were up 27% in Q3, growth in the U.S. was only 3%

With demand for Gardasil building faster than Merck can produce it, the company this year said it would invest about $1.68 billion on two U.S. plants to significantly boost Gardasil production. Those facilities won't come online for several years.  

RELATED: Hack forces Merck to borrow Gardasil doses from CDC stockpile, slamming Q3 sales

“So, in 2023, that is when we will expect to be able to ramp our supply up to meet the ex-U.S. demand,” Frank Clyburn chief commercial officer, told analysts. “We do believe we can still grow Gardasil over the next several years as we continue to match and move supply to match our demand around the world.” 

Merck does not yet know if that will require hitting up the CDC again for more supplies. Merck spokeswoman Pamela Eisele in an email today reiterated the company is investing in new production "with urgency" to meet the growing global demand.

"We’ll continue to monitor our supply situation and determine whether future borrowings are necessary or when the appropriate time would be to replenish the stockpile," she said. 

Merck has had tap the CDC’s Gardasil stockpile before to cover a significant shortfall. The company borrowed $240 million worth of Gardasil doses in 2017 after a cyberattack crippled its production for several months and reduced sales of the HPV vaccine by 22% in one quarter.

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.